These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37074388)

  • 1. Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    Monschein T; Dekany S; Zrzavy T; Ponleitner M; Altmann P; Bsteh G; Kornek B; Rommer P; Enzinger C; Di Pauli F; Kraus J; Berger T; Leutmezer F; Guger M;
    J Neurol; 2023 Aug; 270(8):3779-3786. PubMed ID: 37074388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    Moser T; Zimmermann G; Baumgartner A; Berger T; Bsteh G; Di Pauli F; Enzinger C; Fertl E; Heller T; Koppi S; Rommer PS; Safoschnik G; Seifert-Held T; Stepansky R; Sellner J
    J Neurol; 2024 Jan; 271(1):374-385. PubMed ID: 37728757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up.
    Buron MD; Christensen JR; Pontieri L; Joensen H; Kant M; Rasmussen PV; Sellebjerg F; Sørensen PS; Bech D; Magyari M
    Mult Scler Relat Disord; 2023 Jun; 74():104713. PubMed ID: 37058764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
    J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis.
    Mathew T; Kamath V; John SK; Netravathi M; Iyer RB; Raghavendra S; Kumar S; Neeharika ML; Gupta S; Murgod U; Shivakumar R; Annadure RK; Ichaporia N; Rohatgi A; Nair SS; Yareeda S; Anand B; Singh P; Renukaradhya U; Arulselvan V; Reddy YM; Surya N; Sarma GRK; Nadig R; Deepalam S; Sharath Kumar GG; Satishchandra P; Singhal BS; Parry G
    Mult Scler Relat Disord; 2022 Oct; 66():104059. PubMed ID: 35908446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
    JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.
    Rodríguez de Castro B; Barbosa CM; Ayastuy Ruiz A; Fernández González B
    Eur J Hosp Pharm; 2021 Mar; 28(2):112-114. PubMed ID: 33608441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
    Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
    Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of natalizumab in persons with multiple sclerosis: 2022 update.
    Morrow SA; Clift F; Devonshire V; Lapointe E; Schneider R; Stefanelli M; Vosoughi R
    Mult Scler Relat Disord; 2022 Sep; 65():103995. PubMed ID: 35810718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of risk management in a natalizumab home infusion procedure.
    Lafontaine JC; Boucher J; Giovannelli J; Petit J; Outteryck O; Balagny S; Zéphir H
    Rev Neurol (Paris); 2023 Oct; 179(8):894-901. PubMed ID: 37202259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S;
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):660-668. PubMed ID: 32234967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
    BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.